ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress
Retrieved on:
Friday, April 14, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Abstract, Antigen, AACR, PS, Therapy, Special Protection Area, Intrinsic termination, RCC, Neoplasm, PSMA, Kidney cancer, CA9, American Association for Cancer Research, Trial of the century, Renal cell carcinoma, CAR, ICT, Risk, Engineering, Carbonic anhydrase 9, SPA, Canadian Aviation Regulations, Ovarian cancer, Tumor microenvironment, Primer, Medical imaging, Pharmaceutical industry, Vaccine
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023.
Key Points:
- Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023.
- These data demonstrate the company’s continued progress towards the enhancement and clinical development of its unique integrated circuit T cell approach for diseases beyond ovarian cancer, including kidney cancer and other solid tumors.
- This is the company's second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
- The following abstracts will be presented as poster presentations during the AACR annual meeting.